Home > Insider Trading > Filing (0001140361-15-026072)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1302573	Oncomed Pharmaceuticals Inc	OMED	Pharmaceutical Preparations (2834)	383572512

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1553354	J. Alicia Hager	C/O Oncomed Pharmaceuticals, Inc. 800 Chesapeake Drive Redwood City CA 94063	Vp & General Counsel	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2015-06-29	1,800	$3.42	16,800	No	4	M	Direct
Common Stock	Disposition	2015-06-29	1,800	$22.67	15,000	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2015-06-29	1,800	$0.00	1,800	$3.42

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
15,652		2018-07-22	No	4	M	Direct

Footnotes

Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 23, 2015.
Includes 15,000 restricted stock units. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) restricted stock unit.
This transaction was executed in multiple trades in prices ranging from $22.49 to $22.89, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
The option is fully vested and exercisable, subject to a limitation of 175,438 shares that can be issued to a single grantee in a 12-month period upon the exercise of awards under the Issuer's 2004 Stock Incentive Plan.